Angelman Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Angelman Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Angelman Syndrome Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Angelman Syndrome Market by downloading the comprehensive report from DelveInsight @ Angelman Syndrome Treatment Market Size
Key Takeaways from the Angelman Syndrome Market
- In September 2024:- Hoffmann-La Roche- A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype. This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion Angelman Syndrome (AS) aged 5-17 years (inclusive) will be enrolled in the study.
- The growth of the Angelman syndrome market is expected to be primarily driven by an expanding patient population and the anticipated introduction of new therapies.
- According to the Angelman Syndrome Foundation, Angelman syndrome is a rare neuro-genetic disorder that occurs in one in 15,000 live births or 500,000 people worldwide. It is caused by a loss of function of the UBE3A gene on the 15th chromosome derived from the mother.
- According to the National Organization for Rare Disorders, Angelman syndrome affects males and females in equal numbers. The prevalence is estimated to be approximately 1 in 12,000-20,000 people in the general population.
- As per Angelman UK, Angelman syndrome is a rare neurological disorder affecting around 1:20,000 births. Characteristic features include delayed development, severe learning difficulties, little or no speech, and issues with movement and balance.
- The leading Angelman Syndrome Companies such as GeneTx Biotherapeutics, GEXVal, Ionis Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Roche, Sarepta Therapeutics, StrideBio, Taysha Gene Therapies, Ultragenyx Pharmaceutical, and many others.
- Promising Angelman Syndrome Therapies such as ION582, GTX-102, and others.
Gain a competitive edge in the Angelman Syndrome Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Angelman Syndrome Treatment Drugs
Angelman Syndrome Epidemiology Segmentation in the 7MM
- Total Angelman Syndrome Prevalent Cases
- Total Angelman Syndrome Diagnosed Prevalent Cases
- Angelman Syndrome Cases associated with Clinical Manifestations
- Angelman Syndrome Treated Cases
Angelman Syndrome Market Insights
Medication such as RISPERDAL (risperidone) may be used to manage hyperactive and socially disruptive behavior, but this should not be used as a long-term solution. Acid reflux (or gastroesophageal reflux) can be common in Angelman syndrome. It can be treated by maintaining an upright position during and after eating, or with medication such as Gaviscon and ranitidine. Also, in rare and extreme cases, a type of surgery called fundoplication may be required. Feeding challenges can be addressed with modified breastfeeding techniques and specialized nipples for infants with suckling difficulties. Gastroesophageal reflux may be managed through upright positioning and medications that promote food passage through the digestive tract. In severe cases, surgical tightening of the esophageal sphincter may be necessary. Constipation can be treated with laxatives.
Discover key developments and opportunities in the Angelman Syndrome Market. Click here to learn more from DelveInsight’s latest report @ Angelman Syndrome Market Size
Angelman Syndrome Treatment Market
Current treatment strategies for Angelman syndrome encompass a multidisciplinary approach aimed at managing symptoms and enhancing quality of life. While there is no cure for Angelman syndrome, interventions such as seizure management with antiepileptic drugs and behavioral therapies play a crucial role in symptom control. Communication support through augmentative and alternative communication methods, along with physical and occupational therapy, targets developmental delays and improves functional abilities. Additionally, supportive services such as special education and support groups provide essential resources for individuals with Angelman syndrome and their families. Ongoing research into experimental therapies, including gene therapy and targeted pharmacological interventions, offers hope for future advancements in Angelman syndrome treatment.
Angelman Syndrome Emerging Drugs Profile
- ION582: Ionis Pharmaceuticals
- GTX-102: Ultragenyx Pharmaceutical
- NNZ-2591: Neuren Pharmaceuticals
Download DelveInsight’s Angelman Syndrome Market report today and stay ahead in this rapidly evolving field. @ Angelman Syndrome Clinical Trials
Scope of the Angelman Syndrome Market Report
- Coverage- 7MM
- Angelman Syndrome Companies- GeneTx Biotherapeutics, GEXVal, Ionis Pharmaceuticals, Neuren Pharmaceuticals, Ovid Therapeutics, PTC Therapeutics, Roche, Sarepta Therapeutics, StrideBio, Taysha Gene Therapies, Ultragenyx Pharmaceutical, and many others.
- Angelman Syndrome Therapies- ION582, GTX-102, and others
- Angelman Syndrome Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Angelman Syndrome Unmet Needs, KOL’s views, Analyst’s views, Angelman Syndrome Market Access and Reimbursement
Download the report to understand which factors are driving Angelman Syndrome Market Trends @ Angelman Syndrome Market Trends
Table of Content
1. Key Insights
2. Executive Summary of Angelman Syndrome
3. Competitive Intelligence Analysis for Angelman Syndrome
4. Angelman Syndrome: Market Overview at a Glance
5. Angelman Syndrome: Disease Background and Overview
6. Patient Journey
7. Angelman Syndrome Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Angelman Syndrome Unmet Needs
10. Key Endpoints of Angelman Syndrome Treatment
11. Angelman Syndrome Marketed Products
12. Angelman Syndrome Emerging Therapies
13. Angelman Syndrome: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Angelman Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Angelman Syndrome Treatment Market Size is expected to grow by 2034, estimates DelveInsight